Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Acorda Therapeutics Inc | ACOR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
11.91 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 8.978 - 24.196 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 11.91 | USD |
Acorda Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
14.79M | 1.24M | - | 131.12M | -65.92M | -53.07 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Acorda Therapeutics News
Date | Time | Source | News Article |
---|---|---|---|
3/25/2024 | 15:01 | Business Wire | Acorda Fourth Quarter/Year End 2023 Update:.. |
1/11/2024 | 07:33 | Edgar (US Regulatory) | Form 8-K - Current report |
1/11/2024 | 07:01 | Business Wire | Acorda Therapeutics to Regain Global Commercialization.. |
12/01/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
11/13/2023 | 15:16 | Edgar (US Regulatory) | Form 8-K - Current report |
11/13/2023 | 15:01 | Business Wire | Acorda Therapeutics Reports Third Quarter 2023 Financial.. |
11/06/2023 | 15:01 | Business Wire | Acorda Third Quarter 2023 Update: Webcast/Conference Call.. |
11/06/2023 | 07:00 | Business Wire | Acorda Therapeutics Announces Biopas Laboratories Submission.. |
8/08/2023 | 15:12 | Edgar (US Regulatory) | Form 8-K - Current report |
8/08/2023 | 15:01 | Business Wire | Acorda Therapeutics Reports Second Quarter 2023 Financial.. |
8/02/2023 | 07:00 | Business Wire | Acorda Therapeutics Announces Launch of New INBRIJA®.. |
8/01/2023 | 07:00 | Business Wire | Acorda Second Quarter 2023 Update: Webcast/Conference Call.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACOR Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 12.50 | 13.18 | 11.811 | 12.08 | 3,106 | -0.59 | -4.72% |
1 Month | 14.09 | 14.75 | 11.811 | 12.87 | 4,525 | -2.18 | -15.47% |
3 Months | 14.45 | 18.00 | 11.811 | 14.67 | 3,786 | -2.54 | -17.58% |
6 Months | 14.785 | 18.00 | 9.10 | 12.69 | 4,963 | -2.88 | -19.45% |
1 Year | 10.818 | 24.196 | 8.978 | 16.86 | 215,795 | 1.09 | 10.09% |
3 Years | 98.40 | 127.20 | 5.222 | 27.86 | 703,823 | -86.49 | -87.90% |
5 Years | 1,568.40 | 1,623.60 | 5.222 | 155.78 | 1,346,309 | -1,556.49 | -99.24% |
Acorda Therapeutics Description
Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States. |